评估全程糖尿病视网膜病变的降脂药物标
Jiahui Cao1, Ting Su1,2, Shuilian Chen1
1Guangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.
The British journal of ophthalmology
|February 3, 2025
概括
过氧体增殖器激活受体玛 (PPARG) 激活可能会降低糖尿病视网膜病变 (DR) 的风险,特别是背景DR和增殖DR (PDR). 这种效应似乎与改善葡萄糖控制有关,这表明PPARG是潜在的治疗点.
科学领域:
- 遗传学和精准医学 遗传学和精准医学
- 眼科医生 眼科 眼科
- 代谢疾病 代谢疾病
背景情况:
- 糖尿病视网膜病变 (DR) 的进展与脂质控制有关.
- 调查脂质特征,药物点和DR之间的因果关系至关重要.
研究的目的:
- 评估脂质特征和降脂药物标与全程糖尿病视网膜病变 (DR) 之间的因果关系.
- 根据这些因素,评估背景DR,严重非扩散性DR (NPDR) 和扩散性DR (PDR).
主要方法:
- 采用双样本门德尔随机化 (MR) 和药物向MR分析.
- 利用了来自全球脂质遗传学联盟,英国生物银行和FinnGen的遗传数据.
主要成果:
- 在脂质特征和全程DR之间没有发现显著的因果关系.
- 增强PPARG显示背景DR (OR=0.12) 和PDR (OR=0.25) 的风险降低.
- 调解分析表明,禁食胰岛素和HbA1c水平调解了PPARG-DR关联.
结论:
- PPARG成为全程DR的有希望的药物标.
- 激活PPARG可能会降低背景DR和PDR的风险.
- PPARG激动剂的保护机制可能涉及降糖效应.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
522
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
522
Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K


